000756 新华制药
已收盘 07-05 15:00:00
资讯
新帖
简况
新华制药:公司拥有线上销售渠道,以及医院、诊所及药店等终端客户
证券之星 · 07-04 17:02
新华制药:公司拥有线上销售渠道,以及医院、诊所及药店等终端客户
新华制药:公司代工生产维生素D3
证券之星 · 06-26
新华制药:公司代工生产维生素D3
新华制药获得发明专利授权:“检测氯酮含量的液相色谱分析方法”
证券之星 · 06-26
新华制药获得发明专利授权:“检测氯酮含量的液相色谱分析方法”
新华制药:鱼油保健品金泽百、金百平、金瑞寿为公司生产
证券之星 · 06-25
新华制药:鱼油保健品金泽百、金百平、金瑞寿为公司生产
新华制药最新公告:近日收到普瑞巴林胶囊药品注册证书
证券之星 · 06-19
新华制药最新公告:近日收到普瑞巴林胶囊药品注册证书
新华制药(000756.SZ)获得普瑞巴林胶囊药品注册证书
智通财经 · 06-19
新华制药(000756.SZ)获得普瑞巴林胶囊药品注册证书
新华制药:感谢您的意见与建议。本公司拥有超过八十年发展历史,是亚洲主要的解热镇痛类药物生产出口基地
证券之星 · 06-18
新华制药:感谢您的意见与建议。本公司拥有超过八十年发展历史,是亚洲主要的解热镇痛类药物生产出口基地
新华制药:子公司已经投产,并能满足国内市场要求
证券之星 · 06-14
新华制药:子公司已经投产,并能满足国内市场要求
新华制药:公司管理层团队一定会认真经营好企业,做强做优做大锚定目标任务努力前行,公司生产经营情况正常
证券之星 · 06-13
新华制药:公司管理层团队一定会认真经营好企业,做强做优做大锚定目标任务努力前行,公司生产经营情况正常
新华制药获得发明专利授权:“氟呐普拉赞中间体的后处理方法”
证券之星 · 06-12
新华制药获得发明专利授权:“氟呐普拉赞中间体的后处理方法”
新华制药:感谢您对公司关注、关心,感谢您的意见与建议
证券之星 · 06-07
新华制药:感谢您对公司关注、关心,感谢您的意见与建议
新华制药(000756.SZ):盐酸纳洛酮注射液通过仿制药一致性评价
智通财经 · 05-31
新华制药(000756.SZ):盐酸纳洛酮注射液通过仿制药一致性评价
新华制药(000756.SZ):胞磷胆碱钠注射液(4ml:0.5g)通过仿制药一致性评价
智通财经 · 05-31
新华制药(000756.SZ):胞磷胆碱钠注射液(4ml:0.5g)通过仿制药一致性评价
新华制药(000756.SZ):碳酸氢钠注射液通过仿制药一致性评价
智通财经网 · 05-29
新华制药(000756.SZ):碳酸氢钠注射液通过仿制药一致性评价
新华制药:感谢您对公司长期关注!有关公司未来展望信息,请参见于巨潮资讯网刊载的公司定期报告
证券之星 · 05-29
新华制药:感谢您对公司长期关注!有关公司未来展望信息,请参见于巨潮资讯网刊载的公司定期报告
新华制药(000756.SZ):草酸艾司西酞普兰片(10mg)取得药品注册证书
智通财经 · 05-22
新华制药(000756.SZ):草酸艾司西酞普兰片(10mg)取得药品注册证书
新华制药:公司一直致力于医药主业发展,努力提升业绩,更好回报股东
证券之星 · 05-17
新华制药:公司一直致力于医药主业发展,努力提升业绩,更好回报股东
新华制药(000756)5月13日主力资金净买入3491.10万元
证券之星 · 05-14
新华制药(000756)5月13日主力资金净买入3491.10万元
新华制药:心脑血管疾病是危害人类健康的重要杀手,如何预防心脑血管疾病一直是公司研究的重要课题之一
证券之星 · 05-10
新华制药:心脑血管疾病是危害人类健康的重要杀手,如何预防心脑血管疾病一直是公司研究的重要课题之一
加载更多
公司概况
公司名称:
山东新华制药股份有限公司
所属行业:
医药制造业
上市日期:
1997-08-06
主营业务:
山东新华制药股份有限公司主要从事开发、制造和销售化学原料药、制剂、医药中间体及其他产品。公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。
发行价格:
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":14.64,"timestamp":1720163019000,"preClose":14.25,"halted":0,"volume":4968550,"delay":0,"floatShares":448000000,"shares":682000000,"eps":0.7134,"marketStatus":"已收盘","marketStatusCode":5,"change":0.39,"latestTime":"07-05 15:00:00","open":14.17,"high":14.65,"low":14.11,"amount":71858800,"amplitude":0.0379,"askPrice":14.64,"askSize":697,"bidPrice":14.63,"bidSize":224,"shortable":0,"etf":0,"ttmEps":0.7134,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"adjPreClose":14.25,"symbolType":"stock","openAndCloseTimeList":[[1720143000000,1720150200000],[1720155600000,1720162800000]],"highLimit":15.68,"lowLimit":12.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":682407635,"pbRate":2.04,"roa":"--","roe":"3.04%","epsLYR":0.74,"committee":-0.641434,"marketValue":9990000000,"floatMarketCap":6556000000,"peRate":20.521446,"changeRate":0.0274,"turnoverRate":0.0111,"status":0},"requestUrl":"/m/hq/s/000756","defaultTab":"news","newsList":[{"id":"2448417595","title":"新华制药:公司拥有线上销售渠道,以及医院、诊所及药店等终端客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2448417595","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448417595?lang=zh_cn&edition=full","pubTime":"2024-07-04 17:02","pubTimestamp":1720083771,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药07月04日在投资者关系平台上答复投资者关心的问题。公司拥有线上销售渠道,以及医院、诊所及药店等终端客户。正如公司2023年度报告披露,2023年正值新华制药创建80周年,公司规模和效益开创历史新高,公司营业收入超过81亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400033754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2446350280","title":"新华制药:公司代工生产维生素D3","url":"https://stock-news.laohu8.com/highlight/detail?id=2446350280","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446350280?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:04","pubTimestamp":1719396256,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月26日在投资者关系平台上答复投资者关心的问题。投资者:你好,上面回答,公司代工维生素D3是指公司生产维生素D3吗?新华制药董秘:您好!公司代工生产维生素D3,谢谢!投资者:2023年的分红什么时候发下来?新华制药董秘:您好!分红派息将在周年股东大会批准后两个月内完成,请关注公司于巨潮资讯网刊载的公告。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600036570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2446735978","title":"新华制药获得发明专利授权:“检测氯酮含量的液相色谱分析方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2446735978","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446735978?lang=zh_cn&edition=full","pubTime":"2024-06-26 03:00","pubTimestamp":1719342040,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示新华制药新获得一项发明专利授权,专利名为“检测氯酮含量的液相色谱分析方法”,专利申请号为CN202111322783.1,授权日为2024年6月25日。今年以来新华制药新获得专利授权18个,较去年同期增加了100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600005026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2446894289","title":"新华制药:鱼油保健品金泽百、金百平、金瑞寿为公司生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2446894289","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446894289?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:03","pubTimestamp":1719306186,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药06月25日在投资者关系平台上答复投资者关心的问题。鱼油保健品金泽百、金百平、金瑞寿为公司生产。公司代工维生素D3。感谢您对公司意见及建议。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500033332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2444425649","title":"新华制药最新公告:近日收到普瑞巴林胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444425649","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444425649?lang=zh_cn&edition=full","pubTime":"2024-06-19 17:10","pubTimestamp":1718788234,"startTime":"0","endTime":"0","summary":"新华制药公告,近日,公司收到国家药品监督管理局核准签发的普瑞巴林胶囊(150mg,75mg)《药品注册证书》。普瑞巴林胶囊用于治疗带状疱疹后神经痛、纤维肌痛,属于《国家基本药物目录》、《国家基本医疗保险、工伤保险和生育保险药品目录(2023年)》乙类品种。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900035467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2444423433","title":"新华制药(000756.SZ)获得普瑞巴林胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2444423433","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444423433?lang=zh_cn&edition=full","pubTime":"2024-06-19 17:01","pubTimestamp":1718787703,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的普瑞巴林胶囊(150mg,75mg)《药品注册证书》。普瑞巴林胶囊用于治疗带状疱疹后神经痛、纤维肌痛。新华制药的普瑞巴林胶囊(150mg、75mg)于2024年6月获得批准,丰富了公司产品系列,有利于进一步提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1137376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2444109316","title":"新华制药:感谢您的意见与建议。本公司拥有超过八十年发展历史,是亚洲主要的解热镇痛类药物生产出口基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2444109316","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444109316?lang=zh_cn&edition=full","pubTime":"2024-06-18 17:02","pubTimestamp":1718701357,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药06月18日在投资者关系平台上答复投资者关心的问题。感谢您的意见与建议。本公司拥有超过八十年发展历史,是亚洲主要的解热镇痛类药物生产出口基地。公司核心竞争力分析请参见巨潮资讯网上公司刊载的定期报告。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061800032942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2443816647","title":"新华制药:子公司已经投产,并能满足国内市场要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2443816647","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443816647?lang=zh_cn&edition=full","pubTime":"2024-06-14 18:02","pubTimestamp":1718359367,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月14日在投资者关系平台上答复投资者关心的问题。投资者:请问同新药业是否已经投产,并满产满销?新华制药董秘:您好!子公司已经投产,并能满足国内市场要求。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400036406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2443657409","title":"新华制药:公司管理层团队一定会认真经营好企业,做强做优做大锚定目标任务努力前行,公司生产经营情况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2443657409","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443657409?lang=zh_cn&edition=full","pubTime":"2024-06-13 17:02","pubTimestamp":1718269338,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月13日在投资者关系平台上答复投资者关心的问题。投资者:管理层团队一定要认真经营好这家企业做强做优做大瞄定目标任务努力前行,公司有存在业绩失速和风险警示情况发生吗?新华制药董秘:您好!公司管理层团队一定会认真经营好企业,做强做优做大锚定目标任务努力前行,公司生产经营情况正常。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300032502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2442310904","title":"新华制药获得发明专利授权:“氟呐普拉赞中间体的后处理方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2442310904","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442310904?lang=zh_cn&edition=full","pubTime":"2024-06-12 02:07","pubTimestamp":1718129228,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示新华制药新获得一项发明专利授权,专利名为“氟呐普拉赞中间体的后处理方法”,专利申请号为CN202211512330.X,授权日为2024年6月11日。今年以来新华制药新获得专利授权15个,较去年同期增加了66.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200002650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2441032411","title":"新华制药:感谢您对公司关注、关心,感谢您的意见与建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2441032411","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441032411?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:03","pubTimestamp":1717750991,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)06月07日在投资者关系平台上答复投资者关心的问题。投资者:公司要做好经营管理工作和做好合规市值管理工作维护二级市场稳定,实现国有资产保值增值,公司如何进行布局新质生产力工作新华制药董秘:您好!感谢您对公司关注、关心,感谢您的意见与建议。有关公司创新性工作情况及公司未来展望,请参见公司于巨潮资讯网刊载的定期报告。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700033287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2439962041","title":"新华制药(000756.SZ):盐酸纳洛酮注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2439962041","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439962041?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:14","pubTimestamp":1717154047,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的盐酸纳洛酮注射液(“该产品”)《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。据悉,盐酸纳洛酮注射液为阿片类受体拮抗药,用于阿片类药物复合麻醉药术后,拮抗该类药物所致的呼吸抑制,促使病人苏醒;用于阿片类药物过量,完全或部分逆转阿片类药物引起的呼吸抑制;解救急性乙醇中毒;用于急性阿片类药物过量的诊断。作为解毒药,盐酸纳洛酮注射液已被纳入2023版国家医保甲类药目录。据有关数据统计显示,2023年中国城市公立医疗机构纳洛酮相关制剂销售额约人民币9.12亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2439962284","title":"新华制药(000756.SZ):胞磷胆碱钠注射液(4ml:0.5g)通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2439962284","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439962284?lang=zh_cn&edition=full","pubTime":"2024-05-31 19:12","pubTimestamp":1717153936,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》,本品增加4ml:0.5g规格获批,并通过仿制药质量和疗效一致性评价。公告称,新华制药的胞磷胆碱钠注射液(4ml:0.5g)于2024年5月获得批准,并通过仿制药质量和疗效一致性评价,有利于扩大产品的市场份额,提升该产品的市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2439510589","title":"新华制药(000756.SZ):碳酸氢钠注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2439510589","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439510589?lang=zh_cn&edition=full","pubTime":"2024-05-29 17:15","pubTimestamp":1716974110,"startTime":"0","endTime":"0","summary":"新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2439280517","title":"新华制药:感谢您对公司长期关注!有关公司未来展望信息,请参见于巨潮资讯网刊载的公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2439280517","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439280517?lang=zh_cn&edition=full","pubTime":"2024-05-29 17:02","pubTimestamp":1716973354,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药05月29日在投资者关系平台上答复投资者关心的问题。有关公司未来展望信息,请参见于巨潮资讯网刊载的公司定期报告。感谢您对公司长期关注,感谢您的意见与建议,欢迎投资者亲临公司实地考察。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052900033436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2437187256","title":"新华制药(000756.SZ):草酸艾司西酞普兰片(10mg)取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437187256","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437187256?lang=zh_cn&edition=full","pubTime":"2024-05-22 16:52","pubTimestamp":1716367946,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的草酸艾司西酞普兰片(10mg)《药品注册证书》。据悉,草酸艾司西酞普兰片是二环氢化酞类衍生物消旋西酞普兰的单一右旋光学异构体,用于治疗抑郁症,治疗伴有或不伴有广场恐怖症的惊恐障碍。相比同类抗抑郁药,草酸艾司西酞普兰片疗效和可接受性更佳,是治疗抑郁症的一线药物。艾司西酞普兰片是《国家基本医疗保险、工伤保险和生育保险药品目录》(2023年版)甲类品种,据有关数据显示,2022年草酸艾司西酞普兰药物在中国公立医疗机构终端销售额约为人民币18.80亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2436991715","title":"新华制药:公司一直致力于医药主业发展,努力提升业绩,更好回报股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2436991715","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436991715?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:02","pubTimestamp":1715940166,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)05月17日在投资者关系平台上答复投资者关心的问题。投资者:公司未来在哪些领域培育新的利润增长点,早日找到平衡点实现业绩价值回归新华制药董秘:您好!公司一直致力于医药主业发展,努力提升业绩,更好回报股东。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700035796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","09939","BK1515","BK1574","000756","BK1161","BK0164"],"gpt_icon":0},{"id":"2435402538","title":"新华制药(000756)5月13日主力资金净买入3491.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435402538","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435402538?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:13","pubTimestamp":1715649189,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月13日收盘,新华制药报收于17.28元,上涨3.91%,换手率6.84%,成交量30.63万手,成交额5.33亿元。近5日资金流向一览见下表:新华制药融资融券信息显示,融资方面,当日融资买入4845.45万元,融资偿还3165.54万元,融资净买入1679.91万元。新华制药主营业务:开发、制造和销售化学原料药、医药制剂、化工及其他产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400008523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2434838915","title":"新华制药:心脑血管疾病是危害人类健康的重要杀手,如何预防心脑血管疾病一直是公司研究的重要课题之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2434838915","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434838915?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:02","pubTimestamp":1715331757,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药05月10日在投资者关系平台上答复投资者关心的问题。心脑血管疾病是危害人类健康的重要杀手,如何预防心脑血管疾病一直是公司研究的重要课题之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000031546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0889},{"period":"3month","weight":-0.14},{"period":"6month","weight":-0.2752},{"period":"1year","weight":-0.3318},{"period":"ytd","weight":-0.3008}],"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"68240万元","compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":-0.0432},{"period":"3month","weight":-0.0364},{"period":"6month","weight":0.0097},{"period":"1year","weight":-0.0823},{"period":"ytd","weight":-0.0058}],"survey":" 山东新华制药股份有限公司主要从事开发、制造和销售化学原料药、制剂、医药中间体及其他产品。公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。","serverTime":1720171537265,"listedPrice":3.45,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}